resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-315-5521
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
resTORbio (NASDAQ:TORC) Frequently Asked Questions
What is resTORbio's stock symbol?
resTORbio trades on the NASDAQ under the ticker symbol "TORC."
How were resTORbio's earnings last quarter?
resTORbio, Inc. (NASDAQ:TORC) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.12. View resTORbio's Earnings History.
When is resTORbio's next earnings date?
What price target have analysts set for TORC?
4 Wall Street analysts have issued 12-month price objectives for resTORbio's shares. Their forecasts range from $23.00 to $28.00. On average, they expect resTORbio's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 261.7% from the stock's current price. View Analyst Price Targets for resTORbio.
What is the consensus analysts' recommendation for resTORbio?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for resTORbio.
Has resTORbio been receiving favorable news coverage?
News articles about TORC stock have trended somewhat negative recently, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. resTORbio earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for resTORbio.
Who are some of resTORbio's key competitors?
Some companies that are related to resTORbio include Dicerna Pharmaceuticals (DRNA), Gossamer Bio (GOSS), Theravance Biopharma (TBPH), Epizyme (EPZM), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), Odonate Therapeutics (ODT), AnaptysBio (ANAB), Spectrum Pharmaceuticals (SPPI), Y-mAbs Therapeutics (YMAB), ANI Pharmaceuticals (ANIP), Phibro Animal Health (PAHC), ZEALAND PHARMA/S (ZEAL), Eagle Pharmaceuticals (EGRX) and Athenex (ATNX).
What other stocks do shareholders of resTORbio own?
Who are resTORbio's key executives?
resTORbio's management team includes the folowing people:
- Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 47)
- Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 60)
- Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 51)
- Ms. Jennifer Robinson, Sr. Director of Investor Relations & Corp. Communication
- Dr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 69)
When did resTORbio IPO?
(TORC) raised $86 million in an IPO on Friday, January 26th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
How do I buy shares of resTORbio?
Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is resTORbio's stock price today?
One share of TORC stock can currently be purchased for approximately $7.05.
How big of a company is resTORbio?
What is resTORbio's official website?
How can I contact resTORbio?
resTORbio's mailing address is 500 BOYLSTON STREET 13TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5521.
MarketBeat Community Rating for resTORbio (NASDAQ TORC)
MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days.
